“…FASN inhibition leads to a decrease in tumor progression through several mechanisms, such as alteration of plasma membrane structure, an increase in cancer cell apoptosis, decrease in palmitate synthesis, and inhibition of Wnt, Akt, and β-catenin oncogenic signaling pathways [ 122 ]. The first-generation of FASN inhibitors, such as Orlistat, C75, and cerulenin, were tested in preclinical studies in different types of cancers, such as mesothelioma, lung, breast, renal, and prostate cancers [ 5 , 121 , 123 ]. However, their antitumoral effect has been associated with several side effects, such as weight loss or anorexia [ 123 ].…”